Excited to have our SHOCK TEAM paper published in @CircAHA, thanks to the extraordinary multidisciplinary team @UofUHealth, #AHAFunded & #NIHFunded. Eagerly anticipating more contributions to the field! @taraloujones @aloboMD @nataliemwall @jadzdanaf @MikeYin19 @StavrosDrakos.

RT @JCardFail: PROs provide valuable insight into pts health status, but can they be used to improve risk prediction in HF?. 💡In this study….

RT @JohnPowerMD: At last—our analysis predicting severe outcomes in ICI-myocarditis is out. With just ECG, LVEF, troponin, and clinical his….

RT @CircHF: Left Atrial Reverse Remodeling in Patients Supported with Durable Left Ventricular Assist Devices and Clinical Implications @Jo….

RT @CPKyriakopoulos: Honored to participate and present our work at another @ISHLT meeting and grateful to our amazing team of clinicians a….

Thrilled to share our work on the cost-effectiveness of MCS in refractory cardiogenic shock #ISHLT2025. Grateful to my mentors & collaborators! Energized by the science and inspired by the people @StavrosDrakos @CPKyriakopoulos @tgiannouchos @TomHanffMD @UCSDCardFellows

Congrats @CPKyriakopoulos and team! In this cohort of CS patients transferred from spoke to hub 🏥, we identified 🔑 factors, both inherent and management-related, linked to better outcomes. Insights to help guide escalation of care! @UCSDCardFellows @UCSDCardiology.

RT @StavrosDrakos: Want to attend #UCARS25 to enjoy the terrific bench-to-bedside agenda but can’t make the trip to scenic SLC, Utah? . Joi….

RT @SpencerCarter55: From a fellowship conversation @UTSWCardfellow with @MarkDrazner to publication with @UofUInternalMed data. Excellent….

RT @Lpa_Doc: Breaking news for the lipid community: the FDA has approved Ionis’ medicine – the first and only treatment for adults with FCS….

RT @StavrosDrakos: 1/ #UCARS25.Agenda: Submit abstract by Jan 5! . Interact with leading experts/guest faculty: @….

RT @CircAHA: Patients with LVAD demonstrate substantial cardiomyocyte regeneration, highlighting a potential therapeutic avenue @frisenjona….

RT @StavrosDrakos: Thank you all for the collaborative research leading to an important discovery! . One more big step towards understandin….

Thrilled to share our study in Circulation! Led by @oibergmann, we found a >6-fold boost in cardiac regeneration in LVAD responders vs healthy hearts. Honored to be part of this transformative research. @UofUCV @UCSDCardiology.

RT @StavrosDrakos: Important insights paving the way forward!.This group of younger patients also has a high probability of VAD-mediated my….

The Shock Team approach for treating refractory CS may be a cost-effective alternative to traditional SoC. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.

PSA estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150,000, while it was also dominant in almost one-third of the simulations

In-hospital and 1-year survival were significantly improved after the implementation of the Shock Team (61.0% vs 47.9%; p=0.04 and 55.0% vs 40.5%; p=0.03, respectively).

Overall, 244 patients, 123 treated by the Shock Team and 121 receiving SoC. Predominantly male (77.5%), mean age of 58 years. Well-matched groups in terms of cardiac risk factors and medical comorbidities. Higher incidence of AKI & CPR in the Shock Team group.

Real-world hospital data was used to compare costs and outcomes, including survival at discharge, 1-year survival, and QALYs gained at 1 year.

We examined patients with refractory CS req MCS, treated with or without a Shock Team at a tertiary academic hospital from 2009-2018